Lam JO, Hurley LB, Lai JB, et al. - Researchers examined how hepatitis C virus (HCV) infection is associated with extrahepatic cancers, and determined the influence of direct-acting antiviral (DAA) treatment on these cancers.

• Using electronic health record data from 2007-2017, a cohort study was conducted in a healthcare delivery system.

• At least one type of cancer was diagnosed in 2,451 people with HCV and 173,548 people without HCV.

• Risk for liver cancer (adjusted incidence rate ratio [aIRR] = 31.4, 95% CI = 28.9-34.0), hematologic cancer (aIRR = 1.3, 95% CI = 1.1-1.5), lung cancer (aIRR = 1.3, 95% CI = 1.2-1.5), pancreatic cancer (aIRR = 2.0, 95% CI = 1.6-2.5), oral/oropharynx cancer (aIRR = 1.4, 95% CI = 1.1-1.8), and anal cancer (aIRR = 1.6, 95% CI = 1.1-2.4) appeared higher among people with HCV vs those without HCV.

• Treatment with DAA was linked with a reduction in the risk of liver cancers and hematologic cancers.